SAB Biotherapeutics, Inc. (SABS)
NCM · Healthcare · Biotechnology
$3.41
-0.29%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$310.3M
Shares Outstanding
91.0M
Exchange
NCM
Currency
USD
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (12.7M) | (15.8M) | (20.0M) | (23.4M) |
| Net Income | 45.4M | (16.9M) | (18.9M) | (22.5M) |
| Diluted EPS | $-0.21 | N/A | $-0.35 | $-0.28 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (28.9M) | (38.1M) | (42.9M) | (49.0M) |
| Net Income | (18.7M) | (42.2M) | (34.1M) | 13.3M |
| Diluted EPS | $-4.31 | $-7.64 | $-3.68 | N/A |